The Potential Therapeutic Effect of Nanomaterials on Central Nervous System Disorders
- 1School of Laboratory Medicine, Jilin Medical University, Jilin, 132013, People’s Republic of China
- 2School of Pharmacy, Jilin Medical University, Jilin, 132013, People’s Republic of China
Abstract
Due to the complex pathological mechanisms of central nervous system (CNS) diseases and the robust barrier function of the blood‒brain barrier (BBB), current therapeutic strategies face bottlenecks, including limited therapeutic efficacy and challenges in drug delivery. Through transmembrane mechanisms such as passive and active transport, nanomedicines markedly improve the efficiency of drug transport across the BBB, offering novel targeted therapeutic approaches for ameliorating CNS diseases. Most existing reviews on nanomedicines focus mainly on research advances in the treatment of glioma, stroke and Alzheimer’s disease (AD), whereas systematic summaries regarding the treatment of depression and drug addiction remain scarce. In addition to reviewing the progress in the use of nanomedicines to treat these common CNS diseases, this paper systematically summarizes the therapeutic advances for depression and drug addiction. The challenges encountered in translating nanomedicine from laboratory-based research to clinical applications are also discussed.
Related
- Engineered peroxisomes and patient-derived iPSC models as potential biomaterial platforms for precision neuroprotection in oxidative stress-driven central nervous system disorders
- The role of nanomedicine in infectious diseases of the central nervous system: a narrative review
- Nanomaterials in Agriculture and Their Potential Hazards: A Review
- Self-Monitoring Theranostic Nanomaterials for Biomedical Imaging and Cancer Therapy: Real-Time Visualization of Biodistribution, Payload Release, and Therapeutic Response
- Nanomedicine strategies for overcoming the blood–brain barrier in central nervous system drug delivery: mechanisms, advances, and challenges
BibTeX
@article{shao2026potential,
title = {{The Potential Therapeutic Effect of Nanomaterials on Central Nervous System Disorders}},
author = {Xiaotong Shao and Zhengyi Li and Jie Zhu and Qiming Kou and Kexin Sun and Yingxue Xue},
journal = {International Journal of Nanomedicine},
year = {2026},
month = nov,
doi = {10.2147/ijn.s632428},
url = {https://doi.org/10.2147/ijn.s632428},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - The Potential Therapeutic Effect of Nanomaterials on Central Nervous System Disorders
AU - Xiaotong Shao
AU - Zhengyi Li
AU - Jie Zhu
AU - Qiming Kou
AU - Kexin Sun
AU - Yingxue Xue
PY - 2026
DA - 2026/11/01
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s632428
UR - https://doi.org/10.2147/ijn.s632428
AB - Due to the complex pathological mechanisms of central nervous system (CNS) diseases and the robust barrier function of the blood‒brain barrier (BBB), current therapeutic strategies face bottlenecks, including limited therapeutic efficacy and challenges in drug delivery. Through transmembrane mechanisms such as passive and active transport, nanomedicines markedly improve the efficiency of drug transport across the BBB, offering novel targeted therapeutic approaches for ameliorating CNS diseases. Most existing reviews on nanomedicines focus mainly on research advances in the treatment of glioma, stroke and Alzheimer’s disease (AD), whereas systematic summaries regarding the treatment of depression and drug addiction remain scarce. In addition to reviewing the progress in the use of nanomedicines to treat these common CNS diseases, this paper systematically summarizes the therapeutic advances for depression and drug addiction. The challenges encountered in translating nanomedicine from laboratory-based research to clinical applications are also discussed.
SN - 1176-9114
SN - 1178-2013
ER -